Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Glioblastoma 3Carcinoma, Renal Cell 2Kidney Neoplasms 1Gliosarcoma 1Glioma 1Ependymoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Sunitinib 27Nivolumab 26pembrolizumab 23Sorafenib 17Everolimus 14Cyclophosphamide 13Interleukin-2 10Bevacizumab 10Radiosurgery 9spartalizumab 8pazopanib 7atezolizumab 7Ipilimumab 7Axitinib 7fludarabine 6aldesleukin 6cabozantinib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gemcitabine 5peginterferon alfa-2b 4avelumab 4Nephrectomy 4Irinotecan 4Introns 4Gene Expression Profiling 4Capecitabine 4lenvatinib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Renal Cell × vitespin × Clear all
NCT01147536 2021-06-03

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Agenus Inc.

Phase 2 Terminated
12 enrolled 5 charts
Genitourinary

Carcinoma, Renal Cell

NCT00126178 2012-09-07

Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

Agenus Inc.

Phase 3 Terminated
600 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡